We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vesper Healthcare Acquisition Corporation | NASDAQ:VSPR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.49 | 11.96 | 12.49 | 0 | 01:00:00 |
Filed Pursuant to Rule 424(b)(3) | |||||
Registration No. 333-257995 | |||||
PROSPECTUS SUPPLEMENT NO. 14 (to prospectus dated May 5, 2022) |
Delaware | 85-1908962 | |||||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
2165 Spring Street Long Beach, CA 90806 | (800) 603-4996 | |||||||
(Address of principal executive offices, including zip code) | Registrant's telephone number, including area code |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Class A Common Stock, par value $0.0001 per share | SKIN | The Nasdaq Capital Market |
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||||||||||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||||||||||
Emerging growth company | ☐ |
EXHIBIT INDEX | ||||||||||||||||||||||||||||||||||||||
No. | Description of Exhibit | Form | File No. | Exhibit | Filing Date | Filed Herewith | ||||||||||||||||||||||||||||||||
2.1 | Agreement and Plan of Merger, dated as of December 8, 2020, by and among Vesper Healthcare Acquisition Corp., Hydrate Merger Sub I, Inc., Hydrate Merger Sub II, LLC, LCP Edge Intermediate, Inc. and LCP Edge Holdco, LLC, in its capacity as the Stockholders’ Representative | 8-K | 001-39565 | 2.1 | December 9, 2020 | |||||||||||||||||||||||||||||||||
3.1 | Second Amended and Restated Certificate of Incorporation of The Beauty Health Company | 8-K | 001-39565 | 3.1 | May 10, 2021 | |||||||||||||||||||||||||||||||||
3.2 | Amended and Restated Bylaws of The Beauty Health Company | 8-K | 001-39565 | 3.2 | May 10, 2021 | |||||||||||||||||||||||||||||||||
4.1 | Indenture, dated as of September 14, 2021, between The Beauty Health Company and U.S. Bank National Association, as trustee | 8-K | 001-39565 | 4.1 | September 14, 2021 | |||||||||||||||||||||||||||||||||
4.2 | Form of certificate representing the 1.25% Convertible Senior Notes due 2026 (included as Exhibit A to Exhibit 4.1) | 8-K | 001-39565 | 4.2 | September 14, 2021 | |||||||||||||||||||||||||||||||||
10.1 | Form of Confirmation for Capped Call Transactions | 8-K | 001-39565 | 10.1 | September 14, 2021 | |||||||||||||||||||||||||||||||||
10.2# | Employment Agreement, dates as of January 20, 2022, between Andrew Stanleick, Edge Systems LLC d/b/a The HydraFacial Company and The Beauty Health Company | 8-K | 001-39565 | 10.1 | January 20, 2022 | |||||||||||||||||||||||||||||||||
31.1* | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||||||||||||||||||||||||||||
31.2* | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||||||||||||||||||||||||||||
32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | 10-Q | 001-39565 | 32.1 | May 10, 2022 | |||||||||||||||||||||||||||||||||
32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | 10-Q | 001-39565 | 32.2 | May 10, 2022 | |||||||||||||||||||||||||||||||||
101.INS** | Inline XBRL Instance Document | 10-Q | 001-39565 | 101.INS | May 10, 2022 | |||||||||||||||||||||||||||||||||
101.SCH** | Inline XBRL Taxonomy Extension Schema Document | 10-Q | 001-39565 | 101.SCH | May 10, 2022 | |||||||||||||||||||||||||||||||||
101.CAL** | Inline XBRL Taxonomy Extension Calculation Linkbase Document | 10-Q | 001-39565 | 101.CAL | May 10, 2022 | |||||||||||||||||||||||||||||||||
101.DEF** | Inline XBRL Taxonomy Extension Definition Linkbase Document | 10-Q | 001-39565 | 101.DEF | May 10, 2022 | |||||||||||||||||||||||||||||||||
101.LAB** | Inline XBRL Taxonomy Extension Labels Linkbase Document | 10-Q | 001-39565 | 101.LAB | May 10, 2022 |
EXHIBIT INDEX | ||||||||||||||||||||||||||||||||||||||
No. | Description of Exhibit | Form | File No. | Exhibit | Filing Date | Filed Herewith | ||||||||||||||||||||||||||||||||
101.PRE** | Inline XBRL Taxonomy Extension Presentation Linkbase Document | 10-Q | 001-39565 | 101.PRE | May 10, 2022 | |||||||||||||||||||||||||||||||||
104** | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 attachments |
THE BEAUTY HEALTH COMPANY | |||||||||||
Date: | December 15, 2022 | By: | /s/ Andrew Stanleick | ||||||||
Name: | Andrew Stanleick | ||||||||||
Title: | Chief Executive Officer | ||||||||||
(Principal Executive Officer) | |||||||||||
Date: | December 15, 2022 | By: | /s/ Liyuan Woo | ||||||||
Name: | Liyuan Woo | ||||||||||
Title: | Chief Financial Officer | ||||||||||
(Principal Accounting Officer and Financial Officer) |
1 Year Vesper Healthcare Acquis... Chart |
1 Month Vesper Healthcare Acquis... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions